A synthetic biology approach to probing nucleosome symmetry

  1. Yuichi Ichikawa
  2. Caitlin F Connelly
  3. Alon Appleboim
  4. Thomas CR Miller
  5. Hadas Jacobi
  6. Nebiyu A Abshiru
  7. Hsin-Jung Chou
  8. Yuanyuan Chen
  9. Upasna Sharma
  10. Yupeng Zheng
  11. Paul M Thomas
  12. Hsuiyi V Chen
  13. Vineeta Bajaj
  14. Christoph W Müller
  15. Neil L Kelleher
  16. Nir Friedman
  17. Daniel NA Bolon
  18. Oliver J Rando  Is a corresponding author
  19. Paul D Kaufman  Is a corresponding author
  1. University of Massachusetts Medical School, United States
  2. The Hebrew University, Israel
  3. The Francis Crick Institute, United Kingdom
  4. Northwestern University, United States
  5. European Molecular Biology Laboratory (EMBL), Germany

Abstract

The repeating subunit of chromatin, the nucleosome, includes two copies of each of the four core histones, and recent studies have reported that asymmetrically-modified nucleosomes occur at regulatory elements in vivo. To probe the mechanisms by which histone modifications are read , we designed an obligate pair of H3 heterodimers, termed H3X and H3Y, which we extensively validated genetically and biochemically. Comparing effects of asymmetric histone tail point mutants with those of symmetric double mutants revealed that a single methylated H3K36 per nucleosome was sufficient to silence cryptic transcription in vivo. We demonstrate the utility of this system for analysis of histone modification crosstalk, using mass spectrometry to separately identify modifications on each H3 molecule within asymmetric nucleosomes. The ability to generate asymmetric nucleosomes in vivo and in vitro provides a powerful and generalizable tool to probe the mechanisms by which H3 tails are read by effector proteins in the cell.

Article and author information

Author details

  1. Yuichi Ichikawa

    Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Caitlin F Connelly

    Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Alon Appleboim

    School of Computer Science and Engineering, The Hebrew University, Jerusalem, Israel
    Competing interests
    The authors declare that no competing interests exist.
  4. Thomas CR Miller

    Molecular Machines Laboratory, The Francis Crick Institute, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  5. Hadas Jacobi

    School of Computer Science and Engineering, The Hebrew University, Jerusalem, Israel
    Competing interests
    The authors declare that no competing interests exist.
  6. Nebiyu A Abshiru

    National Resource for Translational and Developmental Proteomics, Northwestern University, Evanston, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Hsin-Jung Chou

    Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Yuanyuan Chen

    Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Upasna Sharma

    Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Yupeng Zheng

    National Resource for Translational and Developmental Proteomics, Northwestern University, Evanston, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Paul M Thomas

    National Resource for Translational and Developmental Proteomics, Northwestern University, Evanston, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Hsuiyi V Chen

    Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Vineeta Bajaj

    Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Christoph W Müller

    Structural and Computational Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  15. Neil L Kelleher

    National Resource for Translational and Developmental Proteomics, Northwestern University, Evanston, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8815-3372
  16. Nir Friedman

    School of Computer Science and Engineering, The Hebrew University, Jerusalem, Israel
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9678-3550
  17. Daniel NA Bolon

    Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, United States
    Competing interests
    The authors declare that no competing interests exist.
  18. Oliver J Rando

    Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, United States
    For correspondence
    Oliver.Rando@umassmed.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1516-9397
  19. Paul D Kaufman

    Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Medical School, Worcester, United States
    For correspondence
    paul.kaufman1@umassmed.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3089-313X

Funding

National Institute of General Medical Sciences (R01GM100164)

  • Yuichi Ichikawa
  • Caitlin F Connelly
  • Hsin-Jung Chou
  • Hsuiyi V Chen
  • Oliver J Rando
  • Paul D Kaufman

European Commission (340712)

  • Alon Appleboim
  • Hadas Jacobi
  • Nir Friedman

National Institute of General Medical Sciences (P41GM108569)

  • Nebiyu A Abshiru
  • Yupeng Zheng
  • Paul M Thomas
  • Neil L Kelleher

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2017, Ichikawa et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,788
    views
  • 526
    downloads
  • 21
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yuichi Ichikawa
  2. Caitlin F Connelly
  3. Alon Appleboim
  4. Thomas CR Miller
  5. Hadas Jacobi
  6. Nebiyu A Abshiru
  7. Hsin-Jung Chou
  8. Yuanyuan Chen
  9. Upasna Sharma
  10. Yupeng Zheng
  11. Paul M Thomas
  12. Hsuiyi V Chen
  13. Vineeta Bajaj
  14. Christoph W Müller
  15. Neil L Kelleher
  16. Nir Friedman
  17. Daniel NA Bolon
  18. Oliver J Rando
  19. Paul D Kaufman
(2017)
A synthetic biology approach to probing nucleosome symmetry
eLife 6:e28836.
https://doi.org/10.7554/eLife.28836

Share this article

https://doi.org/10.7554/eLife.28836

Further reading

    1. Chromosomes and Gene Expression
    2. Structural Biology and Molecular Biophysics
    Liza Dahal, Thomas GW Graham ... Xavier Darzacq
    Research Article

    Type II nuclear receptors (T2NRs) require heterodimerization with a common partner, the retinoid X receptor (RXR), to bind cognate DNA recognition sites in chromatin. Based on previous biochemical and overexpression studies, binding of T2NRs to chromatin is proposed to be regulated by competition for a limiting pool of the core RXR subunit. However, this mechanism has not yet been tested for endogenous proteins in live cells. Using single-molecule tracking (SMT) and proximity-assisted photoactivation (PAPA), we monitored interactions between endogenously tagged RXR and retinoic acid receptor (RAR) in live cells. Unexpectedly, we find that higher expression of RAR, but not RXR, increases heterodimerization and chromatin binding in U2OS cells. This surprising finding indicates the limiting factor is not RXR but likely its cadre of obligate dimer binding partners. SMT and PAPA thus provide a direct way to probe which components are functionally limiting within a complex TF interaction network providing new insights into mechanisms of gene regulation in vivo with implications for drug development targeting nuclear receptors.

    1. Cancer Biology
    2. Chromosomes and Gene Expression
    Ananda Kishore Mukherjee, Subhajit Dutta ... Shantanu Chowdhury
    Research Article

    Telomeres are crucial for cancer progression. Immune signalling in the tumour microenvironment has been shown to be very important in cancer prognosis. However, the mechanisms by which telomeres might affect tumour immune response remain poorly understood. Here, we observed that interleukin-1 signalling is telomere-length dependent in cancer cells. Mechanistically, non-telomeric TRF2 (telomeric repeat binding factor 2) binding at the IL-1-receptor type-1 (IL1R1) promoter was found to be affected by telomere length. Enhanced TRF2 binding at the IL1R1 promoter in cells with short telomeres directly recruited the histone-acetyl-transferase (HAT) p300, and consequent H3K27 acetylation activated IL1R1. This altered NF-kappa B signalling and affected downstream cytokines like IL6, IL8, and TNF. Further, IL1R1 expression was telomere-sensitive in triple-negative breast cancer (TNBC) clinical samples. Infiltration of tumour-associated macrophages (TAM) was also sensitive to the length of tumour cell telomeres and highly correlated with IL1R1 expression. The use of both IL1 Receptor antagonist (IL1RA) and IL1R1 targeting ligands could abrogate M2 macrophage infiltration in TNBC tumour organoids. In summary, using TNBC cancer tissue (>90 patients), tumour-derived organoids, cancer cells, and xenograft tumours with either long or short telomeres, we uncovered a heretofore undeciphered function of telomeres in modulating IL1 signalling and tumour immunity.